GLP-1 Market
LLY $1183.46 ▲ +0.1% NVO $38.80 ▲ +0.5% PFE $28.67 ▲ +0.9% VKTX $35.56 ▼ -3.2% KLRA $11.21 ▼ -6.4% GPCR $35.93 ▼ -0.2% RHHBY $54.41 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Metyrapone

Company
Mayo Clinic
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 26, 2026

Find a Clinical Trial Near Me

See recruiting studies for Metyrapone and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05563467

    Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

    Not yet reported Maria Sklodowska-Curie National Research Institute of Oncology 24 participants Est. completion 2027-05-31 4 sites Stand-alone
    Other conditions: Adrenocortical Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06801249

    Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome

    Not yet reported IRCCS Azienda Ospedaliero-Universitaria di Bologna 50 participants Est. completion 2025-02-17 3 sites
    Other conditions: Adrenal Incidentalomas, Cushing Syndrome
    View official trial listing →
  • Recruiting NCT NCT07138274

    Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

    Not yet reported Mayo Clinic 90 participants Est. completion 2031-12 1 site Stand-alone
    Other conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
    View official trial listing →
  • Recruiting NCT NCT07268222

    Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

    Not yet reported Laikο General Hospital, Athens 150 participants Est. completion 2027-11-25 1 site
    Other conditions: Mild Autonomous Cortisol Secretion (MACS)
    View official trial listing →
  • Recruiting NCT NCT07494084

    Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

    Not yet reported Washington State University 48 participants Est. completion 2029-07 1 site
    Other conditions: Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
    View official trial listing →
  • Status unknown NCT NCT00006270

    Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury

    National Center for Research Resources (NCRR) 32 participants 2 sites
    Other conditions: Brain Injury, Craniocerebral Trauma
    View official trial listing →
  • Status unknown NCT NCT00033098

    Cocaine-Metyrapone Interaction Study - 1

    Not yet reported National Institute on Drug Abuse (NIDA) 12 participants Est. completion 2002-05 1 site
    Other conditions: Cocaine-Related Disorders, Infusions, Intravenous
    View official trial listing →
  • Completed NCT NCT00125554

    Metyrapone as Additive Treatment in Major Depression

    Not yet reported Universitätsklinikum Hamburg-Eppendorf 63 participants Est. completion 2001-07 1 site
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00426608

    To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

    Not yet reported GlaxoSmithKline 20 participants Est. completion 2007-01-08 1 site Stand-alone
    Other conditions: Depressive Disorder and Anxiety Disorders
    View official trial listing →
  • Completed NCT NCT00567814

    A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

    Not yet reported Embera NeuroTherapeutics, Inc. 45 participants Est. completion 2008-11 1 site
    Other conditions: Cocaine Dependence, Cocaine Addiction
    View official trial listing →
  • Completed NCT NCT01375920

    Antiglucocorticoid Augmentation of antiDepressants in Depression

    Not yet reported Jane Barnes 190 participants Est. completion 2013-06 11 sites
    Other conditions: Depression
    View official trial listing →
  • Status unknown NCT NCT01620684

    Cortisol and Nutritional Sympathetic Responsiveness

    Not yet reported Baker Heart Research Institute 24 participants 1 site
    Metabolic syndrome Other conditions: Obesity, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT01673087

    Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures

    Not yet reported University of Michigan 256 participants Est. completion 2017-08-15 1 site Stand-alone
    Other conditions: Stress
    View official trial listing →
  • Completed NCT NCT02297945

    Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

    Not yet reported HRA Pharma 50 participants Est. completion 2020-04-29 36 sites Stand-alone
    Other conditions: Cushing's Syndrome
    View official trial listing →
  • Completed NCT NCT02368379

    Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome

    Not yet reported Nationwide Children's Hospital 23 participants Est. completion 2016-08 1 site
    Other conditions: Prader Willi Syndrome, Adrenal Insufficiency
    View official trial listing →
  • Completed NCT NCT02406066

    Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)

    Not yet reported Embera NeuroTherapeutics, Inc. 24 participants Est. completion 2016-06 2 sites
    Other conditions: Cocaine Use Disorder, Tobacco Use Disorder
    View official trial listing →
  • Completed NCT NCT02856854

    A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

    Not yet reported Embera NeuroTherapeutics, Inc. 18 participants Est. completion 2017-07-25 1 site Stand-alone
    Other conditions: Cocaine Use Disorder
    View official trial listing →
  • Completed NCT NCT03404817

    Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

    Not yet reported Embera NeuroTherapeutics, Inc. 9 participants Est. completion 2018-06-07 1 site
    Other conditions: Cocaine Use Disorder
    View official trial listing →
  • Status unknown NCT NCT03491696

    Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.

    Not yet reported Centre Hospitalier Rouffach 14 participants Est. completion 2022-09 2 sites Stand-alone
    Other conditions: Depressive Disorder, Hormone Disturbance
    View official trial listing →
  • Completed NCT NCT04501874

    A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

    Not yet reported Embera NeuroTherapeutics, Inc. 82 participants Est. completion 2022-10-15 4 sites
    Other conditions: Cocaine Use Disorder
    View official trial listing →
  • Status unknown NCT NCT04868253

    Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

    Not yet reported, Not yet reported Rose Research Center, LLC 25 participants Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: Smoking Cessation, Tobacco Use Disorder
    View official trial listing →
  • Terminated NCT NCT04933916

    Study of EMB-001 as a Potential Smoking Cessation Treatment

    Not yet reported, Not yet reported Embera NeuroTherapeutics, Inc. 16 participants Est. completion 2023-05-01 2 sites Stand-alone
    Other conditions: Tobacco Use Disorder
    View official trial listing →
  • Completed NCT NCT05167084

    Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals

    Not yet reported Eleonora Seelig 20 participants Est. completion 2023-06-08 1 site Stand-alone
    Other conditions: Glucocorticoid Effect
    View official trial listing →
  • Completed NCT NCT05255900

    Effects of Metyrapone in Patients With Hypercortisolism

    Istituto Auxologico Italiano 20 participants Est. completion 2025-12-31 1 site
    Other conditions: Hypercortisolism
    View official trial listing →
  • Completed NCT NCT05919992

    The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve)

    Not yet reported Eleonora Seelig 24 participants Est. completion 2024-07-25 1 site Stand-alone
    Other conditions: Glucocorticoid Effect
    View official trial listing →
  • Active, not recruiting NCT NCT06106295

    Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

    Not yet reported Mayo Clinic 30 participants Est. completion 2028-02-01 1 site Stand-alone
    Other conditions: Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
    View official trial listing →
  • Completed NCT NCT06556277

    Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake

    Not yet reported Eleonora Seelig 23 participants Est. completion 2026-02-25 1 site Stand-alone
    Other conditions: Glucocorticoids, Overweight and Obesity, Overeating
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Metyrapone, Metopirone, Metyrapone 250 mg Oral Tablets

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.